CAS FORMULATIONSTM (File label CASFORM)
This file is exclusive to STNext.

Subject
Coverage••••• Food• Materials• Pharmaceuticals**Areas of focus

File Type

Formulations, Substances, Bibliographic

Features

Thesauri

None.

Alerts (SDIs)

Weekly, Biweekly (default), Monthly

Agroscience *Coatings
Consumer goods
Cosmetics*

CAS Registry
Number® IdentifiersPage Images

Keep & Share




SLART




Learning Database

Structures

RecordContent• Bibliographic information and abstracts for patents and journal articles reporting
formulations• Information about the ingredients included in formulations, including CAS Registry
Numbers• Information about the experimental activity of formulations• Text extracted from drug product inserts reported in the DailyMed database

File SizeMore than 4.5 million records (01/2022)

Coverage• Formulations from English language patents in Subject Coverage areas, 1996 –present• Formulations from selected patents originally published in Chinese, French, German,
Japanese, and Korean• Formulations from journal articles, 2014 – present• Drug product inserts from the DailyMed database

Updates

Several times per week

Language

English

Database
Producer

Chemical Abstracts Service
2540 Olentangy River Road
P.O. Box 3012
Columbus, Ohio 43210-0012 USA
Phone: 800-753-4227 (North America)
Phone: 614-447-3700 (worldwide)Fax:
614-447-3751
Email: help@cas.org
Copyright Holder

January 2022

2
CAS FORMULATIONS

Sources• Patents• Journals• Drug Product Inserts

User Aids• Support and training materials areavailable on the web: www.cas.org

Clusters

None

RelatedDatabases• CAplus• CAS Registry

January 2022

• Online Helps (HELP DIRECTORY lists
all help messages available)• STNGUIDE3CAS FORMULATIONS

Search and Display Field Codes
Fields that allow left truncation are indicated by an asterisk (*). The minimum stem length for left truncation isfour (4) characters.

General Search Fields

Search Field Name

SearchCode

Basic Index * - Contains single
words from Title (TI), Abstract(AB), Chemical Name (CN),Component Name (CNM),
Formulation Description (FD),
Notes fields (Component Note
(CNO), Group Note (GNO),
Experimental Activity Note (EAN),
Product Activity Note (NOTE) andProcess Note (NOTE)), andVocabulary fields (Group (GVO),
Component (CVO), Product(PVO), Target (TVO) and Solvent(SVO)). Also includes CAS
Registry Numbers. (Left truncation
allowed for all text fields in the
Basic Index other than Chemical
Name and Vocabulary fields.)

None(or /BI)

Abstract */AB

Accession Number
Attribution (1)Author (Inventor) (2)

/AN
/ATTR
/AU (or/IN)

Component Form Description/CFR

Component Function Description/CFU

Component Markush Description
Component Count (3)Component Registry Number
Chemical Name
Component Name(s) (4)

/CMD
/CMPC
/CMPRN/CN/CNM

Component Note*
Chemical Name Segment*
Component Optionality
CAplus Accession Number
Component Vocabulary
Document Number(CA Abstract
Number)Delivery Route
Document Type

/CNO
/CNS
/COP
/CPAN
/CVO
/DN

Experimental Activity Description
Experimental Activity Note*
Entry Date (3)Field Availability

/EAD
/EAN
/ED
/FA

/DR
/DT

Display
Codes

Search Examples
S HERBICIDES FLUOROCARBON?
S THICKENER(W)SOLUTIONSS TOPICAL ANESTHETIC/BIS 1071-83-6

S (WATER(1W)OIL)/AB
S HIGH TEMP?/AB
S (HIV(W)TREAT?)/AB
S 2019:51550/AN
S DAILYMED/ATTRS SILBIGER SCOTT M/AU
S ANON/AU
S O NEILL V?/AU
S POWDER/CFR

AB, ANTE,
CCN,GCN, CNM,
CNO, CVO, EAN,
FD, GNO, GVO,
PNTE, PVO, SVO,
RN, TI, TVO

AB
AN
ATTR
AU, INCFR

S ENDOTHELIN RECEPTOR AINHIBITORS/CFU
S MARKUSH/CMD
S 1/CMPC
S 9004-65-3/CMPRNS PROPYLENE GLYCOL/CNS SORBITOL/CNM
S STEAMIC QOS?/CNM
S OLIVE VINEGAR/CNO
S METHYLACETALDEHYDE/CNS
S MANDATORY/COP
S 2019:656160/CPANS METHYLGLYCOSIDES/CVO
S 169:80023/DN

COMPONENT,CFUS INTRAOCULARLY/DR
S INSERT/DT
S JOURNAL/DT
S PATENT/DT
S HALF-LIFE/EAD
S FUNGICIDE/EAN
S 20191003/ED
S CN/FA
S TI/FA

PRODUCT
BIB

CMD
BIB
RN, CMPRN
CCN, GCN
CNM
COMPONENT
CCN, GCNCOPCPANCOMPONENT,CVO
DN

PRODUCTPRODUCT
ED--January 2022

4
CAS FORMULATIONS

Search Field Name

SearchCode

Search Examples

Formulation Description*
FeatureFormulation NumberGroup Description
Group Form Description
Group Function
Group Markush Description
Group Note*

/FD
/FEA
/FN
/GDS
/GFR
/GFU
/GMD
/GNO

S FERTILIZE?/FD
S POWDER?/FEA
S 1000/FN
S MONOMER/GDSS ABRASIVE PARTICLES/GFR
S ACTIVE AGENT/GFU
S MARKUSH/GMD
S ETHYL/GNO

FD
FEA
FN
GDS
GROUP
GROUP
CHEM
GROUP

Group Optionality

/GOP

GROUP

Group Registry NumberGroup VocabularyGroup Count (3)Inventor (or Author)/GRPRN/GVO/GRPC/IN (or/AU)

Journal Title/JT

Location Section Category
Location Section Description
Location Region Page Number
National Drug Codes
Note

/LCC
/LCD
/LCP
/NDC
/NOTE

S MANDATORY/GOPS EXCLUDE/GOP
S 50-21-5/GRPRNS AVENA SATIVA/GVO
S 4/GRPCS SILBIGER SCOTT M/AU
S ANON/AU
S O NEILL V?/AU
S MUCOSAL IMMUNOLOGY/JT
S MUCOSAL IMMUNOL/JT
S IP.COM/JTS CLAIM/LCC
S CLAIM?/LCD
S 21/LCP
S 10019-115-01/NDC
S TORREYA/NOTE

Product Final Physical Form
Product Name CodePatent Number/Kind Code
Product Name Value
Product Purpose
Publication Year (3,5)
Product Vocabulary
CAS Registry Number
Solvent Registry Number
Solvent Vocabulary
Target Description
Target Relationship
Target Type
Target Count (3)Title*
Target Vocabulary
Update (3)

/PF
/PNC
/PNK
/PNV
/PUP
/PY
/PVO
/RN
/SOLRN
/SVO
/TGD
/TGR
/TGT
/TGTC
/TI
/TVO
/UP

S OVAL TABLETS/PF
S GENERIC/PNC
S CN109498798A/PNKS GENISTEIN NANOPARTICLES/PNV
S ANTI-TUSSIVE/PUP
S 2018/PY
S DRUG DELIVERY SYSTEMS/PVO
S 1071-83-6/RN
S 135062-02-1/SOLRNS BENZOLINE/SVO
S “COUGH AND COLD”/TGD
S PREVENTS/TGR
S HALLUCINATIONS/TGT
S 1/TGTCS INFLUENZA/TIS KABUKI SYNDROME/TVO
S 20200121/UP

(1)
(2)
(3)
(4)
(5)

Display
Codes

RN, GRPRNPRODUCTBIB
IN, AU

BIB

LOC
LOC
LOC
NDC
NOTE, ANTE,PNTE
PRODUCT, PF
PNC, PRODUCTPN, PI
PNV, PRODUCTPRODUCTPY, PI
PVO, PRODUCTRN
RN, SOLRN
SVO, PRODUCTPRODUCTPRODUCTPRODUCTPRODUCT
TI, BIB
TVO, PRODUCTUP, BIB

Drug product inserts only.
AU and IN are aliases. To restrict authors to journals, add J/DT to your search. To restrict to patents, add P/DT.
Numeric search field that may be searched with numeric operators or ranges.
Certain product names are represented in CAS FORMULATIONS with registered trademark symbols, trademark symbols, etc.
For those items, use truncation while searching to account for the symbol (e.g., S STEAMIC QOS?/CNM)
No PY information exists for drug product inserts.

January 2022

5
CAS FORMULATIONSPatent Search Fields
SearchCode

Search Field Name
Application Date (1)Application Number
Application Year (1)Inventor (2)Patent Assignee
Patent Country
Patent Number
Patent Number/Kind CodePatent Date (1)(1)(2)

Display
Codes

Search Examples

/AD
/AP
/AY
/IN or /AU
/PA
/PC
/PN
/PNK
/PD

S 20190101/AD
S US2018-16229471/AP
S 2018/AY
S SILBIGER SCOTT M/INS ALNYLAM/PA
S US/PCS WO2019001567/PN
S US 20190083220A1/PNK
S 20200121PD

AD, PI
AP, PI
AY, PIIN (or AU)
PA
PN, PI
PN, PI
PNK, PI
PD,PI

Numeric search field that may be searched with numeric operators or ranges.
AU and IN are aliases in CAS FORMULATIONSSuper Search Fields
Enter a super search code to execute a search in one or more fields that may contain the desired information.
EXPAND may not be used with super search fields. Use EXPAND with the individual field codes instead.
Super Search Field Name

SearchCode

FieldsSearched

Search Examples

S SUCROSE/COMPS OVALBUMIN/GRP
S 1071-83-6/GRN
S 104206-82-8/GRN (L)111991-09-4/GRN
S GLIALKA/CN
S 1071-83-6/RN

Component Information
Group Information
Group/Component Registry
Number(1)

/COMP
/GRP
/GRN

CFU, CNM, CNO, CVO
GFU, GDS, GVO
GRPRN, CMPRN

Chemical Name
Registry Number

/CN
/RN

CCN, GCN
GRPRN, CMPRN,
SOLRN

(1)

Display
Codes
COMP
GRP
RN

CCN or GCN
RN, GRPRN,CMPRN,
SOLRN

Searches for Group Registry Numbers and Component Registry Numbers within the same Group.

DISPLAY and PRINT Formats
Any combination of formats may be used to display or print answers. Multiple codes must be separated by
spaces or commas, e.g., D L1 1-5 TI AU; D L1 1-5 TI,AU. The fields are displayed or printed in the orderrequested.
Hit-term highlighting is available in most fields. In the table-like display of the PI (Patent Information) field,
highlighting is shown by an arrow on the right side pointing to the line that includes the hit terms.
FormatContent

AB
AD
AMT

Abstract Text
Application Date
Dose Amount

AP
AN
ANTE

Application Number
Accession Number (Formulation)
Activity Note

ATTR (1)
AU (IN)AY (2)
CAM

Attribution
Author (or Inventor) Name
Application Year
Component Amount

ExamplesD TI ABD AD or D PI
D CHPRD PRODUCT
D AP or D PI
D 1-5 AND ANTE or D
PRODUCTD ATTR
D AU or D IN
D AY or D PI
D CHEM
January 2022

6
CAS FORMULATIONS
CFR
CFU
CMPS
CN
CNM
CNO

Component Form Description (CTSV, CFP, CFD)
Component Function Description
Component Count
Chemical Name
Component Name
Component Note

CNU

Component Number

CPAN (3)
CMPRN
CVO
DN(3)
DOS
DT
EAD
EAM
EAN
ED
FD
FN
GAM
GCN
GDS
GFR
GFU
GLO

CAplus Accession Number
Component Registry Number
Component Vocabulary
Document Number (CA Abstract Number)
Dosage Description
Document Type
Experimental Activity Description
Experimental Activity Measurement
Experimental Activity Note
Entry Date
Formulation Description
Formulation NumberGroup AmountGroup Chemical NameGroup Description
Group Form Description (GTSV, GFP, GFD)Group Function Description
Group Location

GNO

Group Note

GNU

Group Number

GRPRN
GRPS
GVO
JT
JTA
LCC
LCD
LCP
LOC
NDC
NOTE

Group Registry NumberGroup List
Group Vocabulary
Journal Title
Abbreviated Journal Title
Location Section Category
Location Section Description
Location Region Page Number
Location (LCC, LCD, LCP)
National Drug Code
Note

PA
PF
PI
PNC

Patent Assignee
Product Final Physical FormPatent Information Table (PN, PD, AP and AD)
Product Name Type Code (e.g., author, brand)

PNTE

Process Note

PNV

Product Name Value

PVO
PNU

Product Vocabulary
Product Number

January 2022

D CFR
D CFU
D BIB
D CCN GCN
D CNM
D CHEMD CHPRD CHEMD CHPRD COMPONENTD CPAND CMPRN
D CVO
D DN
D PRODUCT
D DT
D PRODUCT
D PRODUCT
D PRODUCT
D ED
D FD
D FN
D CHEMD GCN
D GDS
D GROUP
D GFU
D CHEMD CHPRD GROUPD CHEMD CHPRD CHEMD CHPRD GROUPD GRPRN
D GRPS
D GVO
D JT
D JT
D LCC
D LCD
D LCP
D LOC
D NDC
D NOTED ANTED PNTE
D PA
D PF
D PI
D PNC
D PRODUCT
D PNTED PRODUCT
D PNV
D PRODUCT
D PVO
D CHPRD PRODUCTD TARGET7CAS FORMULATIONS
PY(4)
RN

Publication Year
CAS Registry Number

SOLRN
SUMM
SVO
TGT
TI
TVO
UP

Solvent RN
Group/Component Summary
Solvent Vocabulary
Target Type
Title
Target Vocabulary
Update

(1)
(2)
(3)
(4)

D PY
D RN
D CMPRN
D GRPRND SOLRND SOLRN
D SUMM
D SVO
D TGT
D TI
D TVO
D UP

Drug product inserts only.
No hit term highlighting.
Appears in records sourced from patents and journals only.
PY information in journals does not display.

Predefined DISPLAY and PRINT Formats
FormatContent

ExamplesALL

AN, CPAN, DN, ED, UP, TI, AU, JT, PA, ATTR, DT, PI, FN,
FD, GRPS, GRPC, CMPC, TGTC, AB, LCC, LCD, LCP,
GNU, GCN, RN, GDS, GNO, GFU, GFR, GRA, GMD, GLO,
CMPS, GOP, GVO, GAM, CNU, CRN, CNM, CVO, CCN,
CAM, CFU, CFR, CRA, CMD, CNO, COP, PNC, PNV, PNU,
PUP, FEA, PF, DOS, PVO, DR, EAD, EAN, EAM, TGD,
TGT, TGR, TVO, NOTE, RN, AMT, CN, SVO, NOTE

D ALL

BIB

AN, CPAN, DN, ED, UP, TI, AU, JT, PA, ATTR, DT, PI, FN,
FD, GRPS, GRPC, CMPC, TGTC

D BIB

CHEM

AN, LCC, LCD, LCP, GNU, GCN, RN, GDS, GNO, GFU, GFR,GRA, GMD, GLO, CMPS, GAM, GOP, GDS, CNU, RN,
CNM, CCN, CAM, CFR, CFU, CNO, CRA, CMD, COP

D CHEM

CHPR

AN, LCC, LCD, LCP, GNU, GCN, RN, GDS, GNO, GFU, GFR,
GMD, GLO, CMPS, GOP, GAM, GDS, CN, CNU, RN, CNM,
CCN, CAM, CFU, CFR, CMD, CMD, COP, PNM, PNC, PNV,
PNU, PUP, FEA, PF, DOS, DR, PVO, EAD, EAN, EAM,
TGD, TGT, TGR, TVO, NOTE, RN, AMT, CN, SVO, NOTED CHPRCOMPONENT

AN, CNU, RN, CNM, CCN, CFU, CFR, CAM, CMD, CNO,
COP

D COMPONENTGROUPAN, GNU, CMPS, RN, GFU, GOP, GAM, GDS, GCN, GNO,
GFR, GMD, GLO

D GROUPLCHEM

AN, LCC, LCD, LCP, GNU, GCN, RN, GDS, GNO, GFU, GFR,
GMD, GLO, CMPS, GOP, GVO, GAM, GDS, CN, CNU, RN,
CNM, CVO, CCN, CAM, CFR, CNO, CFU, CMD, COP

D LCHEMPRODUCTAN, PNM, PNC, PNV, PNU, PUP, FEA, PF, DOS, PVO, DR,
EAD, EAN, EAM, TGD, TGT, TGR, TVO, NOTE, RN, AMT,
CN, SVO, PNTE

D PRODUCTSOLVENTAN, PNU, PUP, DR, PF, FEA, RN, CN

D SOLVENT
January 2022

8
CAS FORMULATIONSTARGET

AN, PNU, PUP, FEA, PF, DR, TGD, TGT, TGR

D TARGETSELECT, ANALYZE, and SORT Fields
The SELECT command is used to create E-numbers containing terms taken from the specified field in ananswer set.
The ANALYZE command is used to create an L-number containing terms taken from the specified field in ananswer set.
The SORT command is used to rearrange the search results in either alphabetic or numeric order of thespecified field(s).
Field Name
Abstract
Patent Application Date
Accession Number
Product Activity Note
Application Patent Number
Author Name/ Inventor Name
Patent Application Year
Component Form Description
Component Name
CAplus Accession Number
Component Registry Number
Component Vocabulary
Document Number (CA Abstract Number)
Document Type
Entry Date
Formulation Description
Formulation NumberGroup Registry NumberGroup Vocabulary
Inventor Name/Author Name
Journal Title
Journal Title
Patent Assignee
Patent Publication Date
Patent Number
Product Name Type Code
Process Notes
Product Name Value
Publication Year
Registry Number
Solvent Vocabulary
Title
Target Vocabulary

January 2022

Field Code
AB
AD
AN
ANTE
AP
AU (or IN)
AY
CFR
CNM
CPAN
CMPRN
CVO
DN
DT
ED
FD
FN
GRPRN
GVO
IN (or AU)
JT
JTA
PA
PD
PN
PNC
PNTE
PNV
PY
RN
SVO
TI
TVO

ANALYZE/
SELECT (1)
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

SORT
N
Y
N
N
N
Y
Y
N
N
Y
N
N
N
Y
Y
Y
Y
N
N
Y
Y
Y
N
Y
N
Y
N
Y
Y
N
N
Y
N

9
CAS FORMULATIONS

Sample Record 1=> d allL1

ANSWER 1 OF 8

CASFORMULTNSCOPYRIGHT 2019 ACS on STN

AN
2018:330339 CASFORMULTNSCPAN 2018:518948
DN
168:320861
ED
22 Sep 2019UP
13 Nov 2019
TI
Ocular film dosage form comprising cyclosporineAU
Kim, Sang Wook; Kim, Jeong Tae; Yi, Hong Gi
JT
PCT Int. Appl.
PA
Corepharm Bio Co., Ltd.
DT
PatentPI
PATENT NO.
--------------WO 2018052185

KIND
---A1

DATE
-------20180322

APPLICATION NO.
--------------------WO 2017-KR7426

DATE-------20170712

FN
FD

Form 2
Cyclosporine Eye Film Formulation: Drug Delivery Systems or Ophthalmic
Agent
GRPS G1-G3
GRPC 3
CMPC 3TGTC 1AB

LCC
LCD

Disclosed is a unit dosage form comprising cyclosporine and being
characterized in that the unit dosage form comprises the same amt. as one
dose of cyclosporine, that the cyclosporine is dissolved and present in
the state of a solid soln., and that the unit dosage form is a film forapplication to the eye.
Exampleexample 1, Table 1, 3, 4, 5, test example 1, 2, 3, 4, 5

GROUP G1
GDS Additional ingredients
CMPS C1GOP Mandatory
COMPONENT C1
RN59865-13-3
CNM cyclosporin A
CVO Formulation active agents; Active agents; Formulation active agent;
Formulation active ingredients; Formulation active ingredient; Active
ingredients; Active agent; Active ingredient
CCN Cyclosporin A (9CI, ACI)CCN 1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontane, cyclic peptide
deriv. (ZCI)
CCN 1: PN: US6686454 SEQID: 1 claimed protein; 7: PN: WO2000002548 PAGE: 30
claimed protein; Abrammune; Antibiotic S 7481F1; Arpimune ME; CICPORAL;
Cicloral; Cicloral (antibiotic); Ciclosporin; Ciclosporina Germed; Cipol
N; Ciqorin; Consupren; CyclASol; Cyclo[L-alanyl-D-alanyl-N-methyl-L-leucylN-methyl-L-leucyl-N-methyl-L-valyl-(3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-LJanuary 2022

10
CAS FORMULATIONS

CAM
CFU
COP

leucyl-L-valyl-N-methyl-L-leucyl]; Cyclokat; Cyclosporin; Cyclosporine;
Cyclosporine A; Cypol-N; Debio088; Equoral; Gengraf; Imusporin; NSC
290193; Neoplanta; Neoral; OL 27-400; Optimmune; Papilock Mini; Ramihyphin
A; Restasis; S-Neoral; SDZ-OXL 400; Sandimmun; Sandimmun Neoral; Sandimmun
Optoral; Sandimmune; Sandimmune Neoral; Sang-35; SangCyA; Sigmasporin
Microoral; Zinograf ME
0.015 mg
active agent
Mandatory

GROUP G2
GDS Additional ingredients
CMPS C2GOP Mandatory
COMPONENT C2
RN
9002-89-5
CNM polyvinyl alcohol
CVO Film-forming agents; Film formers; Film-forming additives; Film forming
agent; Film former
CCN Ethenol, homopolymer (9CI, ACI)CCN Vinyl alcohol, polymers (8CI)
CCN 100-27H; 100-37H; 100-40H; 1799S; 1R2110; 9P75R; 9X75RS; 9X75SR; A 10 Coex
Test 14; A-T; A-T (vinyl polymer); AH 17; AH 22; AH 24; AH 26; AL 06; AL
6; AL 6 (polymer); AQ 2117; AR; AR (vinyl polymer); AVB 8041W; AW 401; AX
20; AX 300SN; AX 400TNG; AZF 8035; Acroflex 1; Acroflex 2; Aibon AU
7002FL; Airvol 103; Airvol 107; Airvol 107SF; Airvol 125; Airvol 125SF;
Airvol 165; Airvol 165SF; Airvol 166; Airvol 21-205; Airvol 21-25; Airvol
24-203; Airvol 321LA; Airvol 325; Airvol 325SF; Airvol 350; Airvol 350SF;
Airvol 425; Airvol 502
CAM 0.69 mg
CFU film forming agent
COP Mandatory
GROUP G3
GDS Additional ingredients
CMPS C3GOP Mandatory
COMPONENT C3
RN
57-55-6
CNM Propylene glycol
CVO Plasticizers; Plasticization agents; Softening agents, plasticizers;
Flexibilizers; Plasticizer; Plastics, plasticizers for; Plasticizing
agents; Softening agent (polymer); Plasticiser; Plasticisers; Polymer
softening agents; Plasticizing agent; Plasticizing materials; Plastifying
agent; Flexibilizer; Plastic softening agent; Polymer softening agent;
Plastifying agents; Plasticizing material; Plasticization agent;
Plasticizers agents; Plasticizer agents; Polymer plasticizing agents;
Polymer plasticizing agent; Polymer plasticizer; Structure plasticizing
agent; Structure plasticizing agents
CCN 1,2-Propanediol (8CI, 9CI, ACI)CCN (RS)-1,2-Propanediol; (±)-1,2-Propanediol; (±)-Propylene glycol;
1,2-(RS)-Propanediol; 1,2-Dihydroxypropane; 1,2-Propylene glycol; 1000PG;
2,3-Propanediol; 2-Hydroxypropanol; Adeka PG; Adeka Propylene Glycol PG-P;
BS 12; DC 403; Dowfrost; HCH 195; Isopropylene glycol; Kilfrost ABC K
Plus; Kilfrost ABC-S; Kilfrost DF K Plus; Kollisolv PG; Methylethyl
glycol; Methylethylene glycol; Monopropylene glycol; NSC 69860; Nybrine
NFP; PG 12; PG-T; PG-T (glycol); ProGlyc 55; Propylene glycol; Propyless;
January 2022

11
CAS FORMULATIONS

CAM
CFU
COP
PNC
PNV

Radianol 4713; Safewing MP-I 1938; Safewing MP-IV 2001; Sirlene; Solar
Winter Ban; Solargard P; Susterra PDO; Ucar 35; α-Propylene glycol;
dl-Propylene glycol; DL-1,2-Propanediol
0.075 mL
plasticizer
Mandatory
authorcyclosporine eye film formulation

PRODUCT PA1
PUP ophthalmic agent
PF
Desc: film
PVO Films; Thin films; Two-dimensional films; Film; Thin film; Dry film; Dryfilms; Two-dimensional film; Protective film; Protective films; Protection
film; Ophthalmic agents; Ophthalmic drug; Ophthalmic drugs; Ophthalmic
agent; Eye drugs; Eye drug; Eye treatment drug; Eye treatment drugs; Optic
drug; Optic drugs; Ophthalmic compositions; Ophthalmic compositionDR
ophthalmic
EAD
EAN
EAM

EAD
EAN
EAM

EAD
EAN

ophthalmological activity
the effect of the film on healthy rabbit eye was evaluated after 24 hoursof administration.
Non-Numeric: Observed that there was no visible corneal opacity during theobservation period before and 24 hours after the administration, and there
was no visible erythema or edema in the conjunctival region., Desc:
ophthalmological activity
ophthalmological activity
the effect of the film on 10 corneas of a healthy adult, and sensory
evaluation of burning sensation was performed.
Non-Numeric: there is no feeling of burning at all., Desc:
ophthalmological activity

EAM

disintegration rate
the disintegration rate of the film was evaluated by dissolving film in
artificial tears.
Single: 9 seconds, Desc: disintegration rate

EAD
EAM

thickness
Single: 0.010 mm, Desc: thickness

EAD
EAM

weightSingle: 0.72 mg, Plus/Minus: 0.057 mg, Desc: weight

EAD
EAM

tensile strengthSingle: 26.37 N/mm2, Plus/Minus: 1.34 N/mm2, Desc: tensile strength

EAD
EAM

Elongation
Single: 165.21 %, Plus/Minus: 3.93 %, Desc: Elongation

EAD
EAN
EAM

cyclosporine dissolution state
the cyclosporine dissolution state in a film was evaluated.
Non-Numeric: No microscopic traces of drug particles were observed on thesurface of the film under the optical microscope and field emission
scanning electron microscope., Desc: cyclosporine dissolution state

PRODUCT PA2
PUP drug delivery systems
PVO Drug delivery systems; Drug delivery system; Pharmaceutical delivery
systems; Delivery systems; DDS; Pharmaceutical composition; Therapeutic
January 2022

12
CAS FORMULATIONS
compound delivery system; Drug delivery device; Drug delivery;
Pharmaceutical compn.; Pharmaceutical compositions; Drug delivery devices;
Therapeutic compound delivery systems
TGR
TGT
TVO

delivers
drug
Drugs; Medicaments; Pharmaceutical; Drug; Medicines; Prophylactic agents;
Therapeutic agents; Chemotherapeutic agents; Pharmacological agents;
Chemotherapeutics; Chemotherapy drugs; Medicament; Pharmacological agent;
Prophylactic agent; Therapeutic agent; Chemotherapeutic agent

PNTE cyclosporin A is dissolved or dispersed in a solution composed ofpolyvinyl alcohol, a solvent and a plasticizer using a magnetic stirrer.
the solution was then degassed using an ultrasonic disperser (sonicator)
and the solution was cast on a suitable substrate to produce a film. theresulting film was cut to a size of 0.5 x 0.5 cm and the final product was
obtained.

Sample Record 2=> d bibL1

ANSWER 1 OF 8

CASFORMULTNSCOPYRIGHT 2019 ACS on STN

AN
2018:330339 CASFORMULTNSCPAN 2018:518948
DN
168:320861
ED
22 Sep 2019UP
13 Nov 2019
TI
Ocular film dosage form comprising cyclosporineAU
Kim, Sang Wook; Kim, Jeong Tae; Yi, Hong Gi
JT
PCT Int. Appl.
PA
Corepharm Bio Co., Ltd.
DT
PatentPI
PATENT NO.
--------------WO 2018052185
FN
FD

KIND
---A1

DATE
-------20180322

APPLICATION NO.
--------------------WO 2017-KR7426

DATE-------20170712

Form 2
Cyclosporine Eye Film Formulation: Drug Delivery Systems or Ophthalmic
Agent
GRPS G1-G3
GRPC 3
CMPC 3TGTC 1January 2022

13
CAS FORMULATIONS

Sample Record 3=> d chemL1

ANSWER 1 OF 8

CASFORMULTNSCOPYRIGHT 2019 ACS on STN

AN
LCC
LCD

2018:330339 CASFORMULTNSExampleexample 1, Table 1, 3, 4, 5, test example 1, 2, 3, 4, 5

GROUP G1
GDS Additional ingredients
CMPS C1GOP Mandatory
COMPONENT C1
RN59865-13-3
CNM cyclosporin A
CCN Cyclosporin A (9CI, ACI)
CAM 0.015 mg
CFU active agent
COP Mandatory
GROUP G2
GDS Additional ingredients
CMPS C2GOP Mandatory
COMPONENT C2
RN
9002-89-5
CNM polyvinyl alcohol
CCN Ethenol, homopolymer (9CI, ACI)
CAM 0.69 mg
CFU film forming agent
COP Mandatory
GROUP G3
GDS Additional ingredients
CMPS C3GOP Mandatory
COMPONENT C3
RN
57-55-6
CNM Propylene glycol
CCN 1,2-Propanediol (8CI, 9CI, ACI)
CAM 0.075 mL
CFU plasticizer
COP Mandatory

January 2022

14
CAS FORMULATIONS

Sample Record 4=> d chpr

L3

ANSWER 1 OF 1

CASFORMULTNS

AN
LCC
LCD

2018:281993 CASFORMULTNSArticlearticle page 2

COPYRIGHT 2019 ACS on STN

GROUP G3
GDS Additional ingredients
CMPS C3GOP Mandatory
COMPONENT C3
RN
9004-65-3
CNM hydroxypropyl methylcellulose
CCN Cellulose, 2-hydroxypropyl methyl ether (9CI, ACI)
CAM 1 %
CFU active agent
CNO purchased from Aldrich (USA).
COP Mandatory
GROUP G5
GDS P-HEMA-VP polymer
CMPS C1-C2; C4-C5
GOP Mandatory
COMPONENT C1
RN
97-90-5
CNM ethylene glycol dimethacrylate
CCN 2-Propenoic acid, 2-methyl-, 1,1'-(1,2-ethanediyl) ester (ACI)
CFU crosslinking agent
CNO purchased from Aldrich (USA).
COP Mandatory
COMPONENT C2
RN
78-67-1
CNM azobisisobutyronitrile
CCN Propanenitrile, 2,2'-(1,2-diazenediyl)bis[2-methyl- (ACI)
CFU initiator
CNO purchased from Aldrich (USA).
COP Mandatory
COMPONENT C4
RN
9003-39-8
CNM poly vinylpyrrolidone
CCN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI, ACI)
CAM 15 wt %CNO purchased from Daejung (Korea).
COP Mandatory
COMPONENT C5
RN
868-77-9
CNM 2 hydroxyethyl methacrylate
CCN 2-Propenoic acid, 2-methyl-, 2-hydroxyethyl ester (9CI, ACI)
January 2022

15
CAS FORMULATIONS
CNO
COP

purchased from Aldrich
Mandatory

PNC
PNV

authorpoly-hydroxypropyl methylcellulose-vinylpyrrolidone hydrogel contact lense

PRODUCT PA1
PUP drug delivery systemPF
Desc: hydrogel
Desc: contact lens
TGR
TGT

delivers
drug

TGR
TGT

treatseye disease

PNTE poly-hydroxypropyl methylcellulose-vinylpyrrolidone hydrogel contact lense
prepared by adding crosslinking agent (EGDMA) and initiator (AIBN) to HEMAin a vial with stirring for 30 min. 80 μL of the solutions mixed with
poly vinylpyrrolidone, then filled onto each plastic molds. polymerization
was carried out by heating in an oven at 100 °C for 4 h, followed
by washing with deionized water to remove the non-copolymerized. opticaldensity of hydrogel contact lenses measured at 290 nm wavelength(UV-spectrophotometer, mega array, Scinco, Korea)was converted to the massunit of the drug using a calibration curve of HPMC (y = 20.22 x-0.0094).
drug storage of contact lenses was performed by immersing a completely
dried contact lens in 1% HPMC for 3 h. In pH change condition, the contactlenses were immersed in a 24 well plate containing PBS (0.2 mL) at the pH
5.80, 6.45, 7.20, and 8.03 for 12 h. In alternative pH condition, HEMA 100
wt %, HEMA-VP 10 wt % and HEMANIPAAm 10 wt % were immersed in a 24 wellplate containing solutions (0.2 mL) of pH 5.80 and solutions of pH 8.03.
immersing was carried out alternately 4 times at intervals of 30 min.

Sample Record 5=> d bib
L3

ANSWER 1 OF 1

CASFORMULTNSCOPYRIGHT 2019 ACS on STN

AN
2018:281993 CASFORMULTNSCPAN 2018:116915
DN
168:380829
ED
22 Sep 2019UP
13 Nov 2019
TI
pH sensitive soft contact lens for selective drug-delivery
AU
Kim, Guenhei; Kim, Hyeok Jung; Noh, Hyeran
JT
Macromolecular Research
DT
JournalFN
Form 4FD
Poly-Hydroxypropyl Methylcellulose-Vinylpyrrolidone Hydrogel Contact
Lense: Drug Delivery System
GRPS G3; G5
GRPC 2
CMPC 5TGTC 2January 2022

16
CAS FORMULATIONS

Sample Record 6
L4

ANSWER 1 OF 1

CASFORMULTNSCOPYRIGHT 2019 ACS on STN

AN
2019:239681 CASFORMULTNSED
28 Oct 2019UP
11 Dec 2019
ATTR DailyMed® is produced by the National Library of Medicine. DailyMed isa registered trademark of the U.S.National Library of Medicine
DT
InsertFN
Form 1
FD
Penicillin V Potassium Tablet; Film Coated: Antibacterial Agent
GRPS G1-G9
GRPC 9CMPC 9TGTC 19

In North America
CAS
STN North America
P.O. Box 3012
Columbus, Ohio 43210-0012 U.S.A.
CAS Customer Center:Phone: 800-753-4227 (North America)
614-447-3700 (worldwide)Fax:
614-447-3751
Email:
help@cas.org
Internet: www.cas.org

January 2022

In Europe
FIZ Karlsruhe
STN Europe
P.O. Box 2465
76012 Karlsruhe
Germany
Phone: +49-7247-808-555
Fax:+49-7247-808-259
Email:
helpdesk@fiz-karlsruhe.de
Internet: www.stn-international.com

In Japan
JAICI (Japan Association forInternational Chemical Information)
STN Japan
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021, Japan
Phone: +81-3-5978-3601 (Technical Service)+81-3-5978-3621 (Customer Service)
Fax:+81-3-5978-3600
Email:
support@jaici.or.jp (Technical Service)customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp